Article: Breast Cancer: FDA Approves New Oral Pill to Treat Common Mutation

The FDA approved Eli Lilly's new oral combo drug for a common breast cancer mutation. The treatment includes Inluriyo (imlunestrant) taken with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutation that has spread after hormone therapy.